|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Inventories, net | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Right-of-use assets | ||||||||||||||||||||
| Investments in non-consolidated affiliates | ||||||||||||||||||||
| Other non-current assets | ||||||||||||||||||||
| Deferred Tax Assets, Tax Deferred Expense | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND EQUITY | ||||||||||||||||||||
| Short-term debt | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued employee liabilities | ||||||||||||||||||||
| Current lease liability | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term debt, net | ||||||||||||||||||||
| Employee benefits | ||||||||||||||||||||
| Non-current lease liability | ||||||||||||||||||||
| Deferred tax liabilities | ||||||||||||||||||||
| Other non-current liabilities | ||||||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||||||
| Common stock (par value $0.01, 250 million shares authorized, 55 million shares issued, 24700000 million shares outstanding as of September 30, 2026 and 26.8 million shares outstanding as of December 31, 2025, respectively) | ||||||||||||||||||||
| Preferred stock (par value $0.01, 50 million shares authorized, none outstanding as of September 30, 2026 and December 31, 2025) | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Treasury stock | ||||||||||||||||||||
| Total Visteon Corporation stockholders’ equity | ||||||||||||||||||||
| Non-controlling interests | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and equity | ||||||||||||||||||||
| Common stock, shares outstanding (in shares) | ||||||||||||||||||||
| Common stock, shares, issued (in shares) | ||||||||||||||||||||
| Common stock, shares authorized (in shares) | ||||||||||||||||||||
| Common stock, par value (in dollars per share) |
Loading...
